Listed

Greenwich LifeSciences, Inc.: Form 10-Q for the period ended Jun 30, 2022

Filed with the SEC on Aug 15, 2022 and accepted by EDGAR at Aug 15, 2022, 17:06 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2022-04-01 to 2022-06-30$633.3kus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2022-01-01 to 2022-06-30$2.3mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2022-04-01 to 2022-06-30−$773.3kus-gaap:OperatingIncomeLoss
Operating income6 months2022-01-01 to 2022-06-30−$2.8mus-gaap:OperatingIncomeLoss
Net income3 months2022-04-01 to 2022-06-30−$746.1kus-gaap:NetIncomeLoss
Net income6 months2022-01-01 to 2022-06-30−$2.7mus-gaap:NetIncomeLoss
Basic EPS3 months2022-04-01 to 2022-06-30−$0.06us-gaap:EarningsPerShareBasic
Basic EPS6 months2022-01-01 to 2022-06-30−$0.21us-gaap:EarningsPerShareBasic
Operating cash flow6 months2022-01-01 to 2022-06-30−$2.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Share repurchases6 months2022-01-01 to 2022-06-30$7.5mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2022-06-30$17.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Total assetsAt period end2022-06-30$17.2mus-gaap:Assets
Current liabilitiesAt period end2022-06-30$229.1kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-06-30$229.1kus-gaap:Liabilities
Shareholders' equityAt period end2022-06-30$17.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-22-022956. Last ingested by Listed: Oct 26, 2026, 16:53 ET. Listed shows no prices and gives no investment advice.